Skip to content
PoliticalRepoPoliticalRepo

Subjects · US

Healthcare

Records whose title is actually about this topic. Use a country filter if the list is still too broad.

1,001 records in US in 2025

All countriesSearch this topic

Records

Bill· HRH.R. 3665 (119th)referred

Medicare Economic Security Solutions Act

United States · United States Congress · 29 May 2025

Medicare Economic Security Solutions Act This bill modifies provisions relating to enrollment periods for Medicare medical services. Among other things, the bill establishes a late enrollment penalty of 15% of monthly premiums and applies the penalty for a period equal to twice the number of months in each 12-month period during which the individual was not enrolled. Currently, the late enrollment penalty is 10% of monthly premiums for each 12-month period during which the individual was not enrolled, and the penalty continues to apply for as long as the individual is enrolled in Medicare medical services. The bill also expands the special enrollment periods to individuals who have health insurance coverage other than through their employer.

Bill· HRH.R. 3644 (119th)referred

Menstrual Equity For All Act of 2025

United States · United States Congress · 29 May 2025

Menstrual Equity For All Act of 2025 This bill expands access to menstrual products (e.g., tampons) in certain locations and for particular groups, such as in schools and for low-income individuals, through federal programs and requirements. It also prohibits state or local sales taxes for these products.  The bill expands access to menstrual products through federal programs by requiring Medicaid to cover such products, establishing grants within the Temporary Assistance for Needy Families (TANF) program to provide benefits to ensure access to such products, authorizing the Emergency Food and Shelter Program to provide menstrual products to homeless individuals, and increasing Social Services Block Grant funding to provide such products to low-income individuals. Also, the bill sets out requirements to make free menstrual products available in federal and state correctional facilities (including Department of Homeland Security detention facilities) and restrooms in federal buildings that are open to the public. Further, the bill (1) establishes grants to provide free menstrual products to students at institutions of higher education, and (2) permits elementary and secondary schools to use certain grant funds to provide menstrual products to students. In addition, the bill requires employers with at least 100 employees to provide free menstrual products for employees. Finally, the bill prohibits states and local governments from taxing retail sales of menstrual products.

Bill· HRH.R. 3639 (119th)referred

VET PFAS Act

United States · United States Congress · 29 May 2025

Veterans Exposed to Toxic PFAS Act or the VET PFAS Act This bill provides eligibility for Department of Veterans Affairs (VA) hospital care and medical services to veterans and their family members (including those in utero) who have specified conditions and resided at a military installation where individuals were exposed to perfluoroalkyl and polyfluoroalkyl substances, commonly known as PFAS. PFAS are man-made and may have adverse human health effects. Hospital care and medical services may not be furnished for a condition that is found to have resulted from a cause other than the exposure to PFAS at a military installation. The VA may provide reimbursement for hospital care or medical services provided to a family member only after the family member or provider has exhausted all claims and remedies otherwise available for payment of such care. For disability compensation purposes, the bill establishes a presumption of service-connection for specified conditions in veterans who served at a military installation at which individuals were exposed to PFAS. Under a presumption of service-connection, specific conditions diagnosed in certain veterans are presumed to have been caused by the circumstances of their military service. Health care benefits and disability compensation may then be awarded.

Bill· HRH.R. 3620 (119th)open

Southcentral Foundation Land Transfer Act of 2025

United States · United States Congress · 29 May 2025

Southcentral Foundation Land Transfer Act of 2025 This bill directs the Department of Health and Human Services (HHS) to convey approximately 3.4 acres in Anchorage, Alaska, to the Southcentral Foundation (SCF) for use in connection with health and social services programs. The conveyance must be made by warranty deed. The conveyance may not (1) require any consideration (such as payment) from the SCF for the property; (2) impose any obligation, term, or condition on the SCF relating to that property; or (3) allow for any U.S. reversionary interest in the property. HHS must be accorded any easement or access to the property as may be reasonably necessary to satisfy any retained obligation or liability of HHS. The bill prohibits the SCF from being liable for certain environmental contamination that occurred on or before the date on which the property is conveyed to the SCF. In turn, HHS may not be liable for any contamination that occurred after the date that the SCF controlled, occupied, and used the property. 

Bill· HRH.R. 3581 (119th)referred

Protect DSH Act

United States · United States Congress · 23 May 2025

Bill· HRH.R. 3589 (119th)referred

RESTORE Act

United States · United States Congress · 23 May 2025

Reproductive Empowerment and Support Through Optimal Restoration Act or the RESTORE ACT This bill explicitly prohibits penalizing health care providers for declining to participate in assisted reproductive technology (e.g., in vitro fertilization). It also modifies services and training relating to reproductive health, especially to support an approach the bill refers to as restorative reproductive medicine . The bill describes restorative reproductive medicine as using methods such as monitoring reproductive health and addressing health conditions that may cause infertility (e.g., endometriosis) to restore reproductive function without using methods such as assisted reproductive technology. The bill prohibits the federal government and entities receiving federal funding from penalizing health care providers that decline to (1) participate in assisted reproductive technology, or (2) facilitate such activities due to religious beliefs or moral convictions. The Department of Health and Human Services (HHS) must update the medical codes for classifying infertility treatments to reflect the latest practices for restorative reproductive medicine.   Also, HHS must expand the Teen Pregnancy Prevention program to include grants to entities focusing on restorative reproductive medicine. HHS must also deem entities providing or teaching restorative reproductive medicine eligible for certain family planning grants, when otherwise eligible. Additionally, HHS must issue reports every three years on the standards of care for diagnosing infertility and reproductive health conditions, require the Reproductive Health National Training Center to provide training on restorative reproductive medicine, develop education within HHS programs on treating male infertility, and expand research on restorative reproductive medicine and reproductive health conditions.

Bill· HRH.R. 3580 (119th)referred

Oversight of Medicare Billing Code Cost Act

United States · United States Congress · 23 May 2025

Oversight of Medicare Billing Code Cost Act This bill requires the Office of the Inspector General of the Department of Health and Human Services to report on the processes for adding, modifying, and removing billing codes under Medicare. The report must include recommendations for administrative and legislative changes that may improve the transparency and oversight of these processes. In addition, the Centers for Medicare & Medicaid Services must annually publish on its website a list of billing codes that were added under Medicare during the previous year, as well as the associated volume and expenditures for such codes.

Bill· SS. 1862 (119th)referred

ORPHAN Cures Act

United States · United States Congress · 22 May 2025

Optimizing Research Progress Hope And New Cures Act or the ORPHAN Cures Act This bill modifies certain provisions under the Medicare Drug Price Negotiation Program with respect to orphan drugs. The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation. The program does not apply to orphan drugs that are approved to treat only one rare disease or condition. The bill modifies these provisions so as to exclude any period in which a drug was an orphan drug from market approval calculations. It also excludes orphan drugs that are approved to treat more than one rare disease or condition from the program.

Bill· SS. 1855 (119th)referred

Care for Military Kids Act

United States · United States Congress · 22 May 2025

Care for Military Kids Act This bill requires a state Medicaid program to consider active-duty members of the Armed Forces and their dependents who are receiving home- and community-based services to be residents of that state even if they are relocated to another state because of their military service, unless the member chooses not to be considered as such. The requirement applies beginning in 2028. The bill provides funds through FY2030 for the Centers for Medicare & Medicaid Services to implement the bill.

Bill· SS. 1906 (119th)referred

Innovative FEED Act of 2025

United States · United States Congress · 22 May 2025

Innovative Feed Enhancement and Economic Development Act of 2025 or the Innovative FEED Act of 2025 This bill provides for the regulation of zootechnical animal food substances as food additives. The bill defines  zootechnical animal food substance  as a substance that is added to the food or drinking water of animals and that affects only the animal's gastrointestinal tract, with the intended purpose of affecting the byproducts of the animal's digestion, reducing foodborne pathogens, or altering the animal's gastrointestinal biome. The definition does not include substances that are used to treat or prevent diseases in animals, hormones, or active ingredients of animal drugs. Labels for zootechnical animal food substances must include a disclaimer that the substance may not be used to treat or prevent diseases in animals. 

Bill· SS. 1912 (119th)referred

Protecting Veteran Community Care Act

United States · United States Congress · 22 May 2025

Protecting Veteran Community Care Act This bill requires the Department of Veterans Affairs (VA) to furnish residential mental health or substance-use services to certain veterans through the Veterans Community Care Program (VCCP). Specifically, the VA must furnish such care if a veteran (1) meets VA criteria for priority admission to a VA Mental Health Residential Rehabilitation Treatment Program and the VA is unable to accommodate priority admission, or (2) has contacted the VA to request such mental health services and the VA is not able to furnish such services in a manner that complies with VA access standards for specialty care provided under the VCCP. The VA must ensure that a referral to an alternate Mental Health Residential Rehabilitation Treatment Program does not take precedence over timely access to mental health or substance-use services unless the referral is requested by the veteran. The VA is prohibited from determining a veteran is ineligible for VCCP care solely because VCCP providers are unable to comply with wait times or access standards. If multiple options for care or services are available, the VA must permit a veteran to elect the option the veteran prefers. Additionally, the bill provides minimum standards for residential mental health or substance-use services provided under the VCCP (e.g., treatment programs or facilities must be licensed and accredited for the specified services).

Bill· SS. 1882 (119th)referred

RESTORE Act

United States · United States Congress · 22 May 2025

Bill· SS. 1911 (119th)referred

HEALTH Panel Act

United States · United States Congress · 22 May 2025

Healthy Equipping And Lending Technical Help Panel Act or the HEALTH Panel Act This bill provides statutory authority for the Panel of Health Advisors within the Congressional Budget Office (CBO). The panel provides expertise and recommendations to CBO to support its analysis and cost estimates relating to health and healthcare. The bill requires the panel to report to the House and Senate Budget Committees on the recommendations the panel provided to CBO and how CBO utilized such recommendations. CBO must publish this report on its website. The bill also requires the panel to consist of 15 members serving three-year terms. The respective chairs and ranking minority members of the House and Senate Budget Committees, and the director of CBO, must each appoint three members to the panel.

Bill· HRH.R. 3546 (119th)referred

Prescription Drug Price Relief Act of 2025

United States · United States Congress · 21 May 2025

Prescription Drug Price Relief Act of 2025 This bill requires the Department of Health and Human Services (HHS) to review brand-name drugs annually for excessive pricing and, if a drug is found to be priced excessively, to void any exclusivity granted to its sponsor. Specifically, HHS must review all brand-name drug prices at least annually and upon petition. If any such drugs are found to be excessively priced, HHS must (1) void any government-granted exclusivity; (2) issue open, nonexclusive licenses for the drugs; and (3) expedite the review of corresponding applications for generic drugs and biosimilar biological products. HHS must also create a public database with its determinations for each drug. An entity accepting an open, nonexclusive license under these provisions must pay a reasonable royalty to the holder of the relevant patent or approved new drug application, and must price the generic drug or biosimilar below the excessive rate. Under the bill, a price is considered excessive if the domestic average manufacturing price exceeds the median price for the drug in Canada, the United Kingdom, Germany, France, and Japan. If a price does not meet this criteria, or if pricing information is unavailable in at least three of these countries, the price is still considered excessive if it is higher than reasonable in light of specified factors, including development cost, revenue, and the size of the affected patient population. The bill also requires drug manufacturers to report specified financial information for brand-name drugs, including research and advertising expenditures.

Bill· SS. 1830 (119th)open

Right to Treat Act

United States · United States Congress · 21 May 2025

PreviousPage 20 of 21Next